CXCL9-11 polymorphisms are associated with liver fibrosis in patients with chronic hepatitis C: a cross-sectional study

Clinical and Translational Medicine

Table 3 Summary of LSM and fibrosis stages according to CXCL9-11 polymorphisms (CXCL9 rs10336, CXCL10 rs3921, and CXCL11 rs4619915) in HCV-infected patients

rs10336	AA	AG	GG	p^a
No.	64	193	132
LSM (kPa)	8.6 (6.1; 12.9)	6.7 (5.3; 8.9)	7.5 (5.6; 11.7)	0.002
F ≥ 2 (≥7.1)	40 (62.5%)	77 (39.9%)	67 (50.8%)	0.004
F ≥ 3 (≥9.5)	28 (43.8%)	44 (22.8%)	47 (35.6%)	0.002
F4 (≥12.5)	17 (26.6%)	26 (13.5%)	28 (21.2%)	0.035

rs3921	CC	CG	GG	p^a
No.	63	191	135
LSM (kPa)	8.6 (6.1; 12.9)	6.7 (5.3; 9.1)	7.6 (5.6; 11.6)	0.001
F ≥ 2 (≥7.1 kPa)	39 (61.9%)	75 (39.3%)	70 (51.9%)	0.003
F ≥ 3 (≥9.5 kPa)	28 (44.4%)	44 (23%)	47 (34.8%)	0.003
F4 (≥12.5 kPa)	17 (27%)	26 (13.6%)	28 (20.7%)	0.038

rs4619915	AA	AG	GG	p^a
No.	63	191	135
LSM (kPa)	8.6 (6.1; 12.9)	6.7 (5.3; 9.1)	7.6 (5.6; 11.6)	0.001
F ≥ 2 (≥ 7.1)	39 (61.9%)	75 (39.3%)	70 (51.9%)	0.003
F ≥ 3 (≥ 9.5)	28 (44.4%)	44 (23.0%)	47 (34.8%)	0.003
F4 (≥ 12.5)	17 (27%)	26 (13.6%)	28 (20.7%)	0.038

p value level of significance LSM liver stiffness measure, kPa kilopascal, F ≥ 2 significant fibrosis, F ≥ 3 advance fibrosis, F4 cirrhosis, CXCL chemokine (C-X-C motif) ligand
Statistical: ^a p values were calculated by KW (continuous variable) or Chi squared test (dichotomous variable). Statistically significant differences are shown in italic